Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_1004_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

31.08.2026

Размер:

26 Мб

Скачать

☆

<<< < Предыдущая 11 12 13 14 15 16 17 18 19 20 21 2223 / 4023 24 25 26 27 28 29 30 31 32 33 34 35 > Следующая >>>

Bariatric andMetabolic Surgery

https://t.me/medicina_free

197

7.8.7 Guidelines

AWMF S3 guideline: Surgery for obesity and metabolic diseases. Register No. 088–001. February 2018. 7 https://www. awmf. org/

uploads/tx_szleitlinien/088- 001l_S3_ChirurgieAdipositas- metabolische- Erkrankungen_2018-

02. pdf

References

Aminian A, Zajichek A, Arterburn DE, Wolski KE,

Brethauer SA, Schauer PR, Kattan MW, Nissen SE (2019) Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 322(13):1271–1282. https://doi.org/10.1001/

jama.2019.14231

Billmann F, El Shishtawi S, Bruckner T, Spitzner A,

Elsheikh M, Müller-Stich BP, Billeter A (2021) Combined non-alcoholic fatty liver disease and type 2 diabetes in severely obese patients—medium term effects of sleeve gastrectomy versus Roux-Y-gastric Bypass on disease markers. Hepatobiliary Surg Nutr; accepted for publication

Chooi YC, Ding C, Magkos F (2019) The epidemiology

of obesity. Metabolism 92:6–10

Rubino F, Shukla A, Pomp A, Moreira M, Ahn SM,

Dakin G (2014) Bariatric, metabolic, and diabetes surgery. What’s in the name? Ann Surg 259: 117–122

Sjöström L (2013) Review of the key results from the

Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 273:219–234

Suggested Reading

Carus T (2014) Operationsatlas Laparoskopische

Chirurgie. Springer, Berlin/Heidelberg

Gentileschi P, Kini S, Catarci M, Gagner M (2002)

Evidence- based medicine: open and laparoscopic bariatric surgery. Surg Endosc 16:736–744

Inabnet WB, DeMaria EJ, Ikramuddin S (2005)

Laparoskopic bariatric surgery. Lippincott Williams & Wilkins, Philadelphia/Baltimore/New York/ London

Karcz K, Thomusch O (eds) (2012) Principles of meta-

bolic surgery. Springer, Berlin/Heidelberg/New York

Lucchese M, Scoparino N (eds) (2015) Minimally inva-

sive bariatic and metabolic surgery. Principles and technical aspects. Springer, Berlin/Heidelberg/ NewYork

Migrone G, Panunzi S, De Gaetano A, Guidone C,

Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an openlabel, single center, randomised controlled trial. Lancet 386:964–973

Rubino F, Kaplan LM, Schauer PR, Cummings DE

(2010b) The diabetes surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 251:399–405

Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti

KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, TaroncherOldenburg G, Cummings DE, Delegates of the 2nd Diabetes Surgery Summit (2017) Metabolic surgery in the treatment algorithm of type 2 diabetes: a joint statement by International Diabetes Organizations. Obes Surg 27:2–21

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian

A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR, Investigators STAMPEDE (2017) Bariatric surgery versus intensive medical therapy for diabetes—5 years outcomes. N Engl J Med 376:641–651

Sundbom M, Näslund E, Vidarsson B, Thorell A,

Ottoson J (2020) Low overall mortality during 10 years of bariatric surgery: nationwide study on 63,469 procedures from the Scandinavian Obesity Registry. Surg Obes Relat Dis 16:65–70

White GE, Courcoulas AP, King WC, Flum DR,

Yanovski SZ, Pomp A, Wolfe BM, Spaniolas K, Pories W, Belle SH (2019) Mortality after bariatric surgery: ndings from a 7-year multicenter cohort study. Surg Obes Relat Dis 15:1755–1765

WHO (2020) Obesity and overweight. https://www. who.

int/newsroom/fact- sheets/detail/obesity- andoverweight; Accessed 15 May 2021

199

https://t.me/medicina_free

Liver, Gallbladder andBile Ducts

KatrinHoffmann andPeterSchemmer

Contents

8.1 Anatomy andPhysiology oftheLiver – 201

8.1.1 Denitions – 201

8.1.2 Macroscopic andMicroscopic Anatomy – 201

8.1.3 Tasks oftheLiver andFunctional Liver Volume – 201

8.1.4 Location – 202

8.1.5 Measured Values – 202

8.1.6 Blood Supply andDrainage – 202

8.1.7 Terminology ofLiver Resections (. Fig.8.1) – 203

8.2 Diseases oftheLiver – 204

8.2.1 Benign Diseases – 204

8.2.2 Malignant Diseases oftheLiver – 206

8.2.3 Technique ofLiver Resection – 210

8.3 Liver Transplantation – 212

8.3.1 General andLegal Basis – 212

8.3.2 Evaluation andFollow-Up ofLiver Function – 213

8.3.3 Indications forLiver Transplantation: Relevant Underlying Diseases inAdults – 214

8.3.4 Contraindications forLiver Transplantation – 215

8.3.5 Surgical Principles – 215

8.4 Anatomy andPhysiology oftheGallbladder andBile Ducts – 217

8.4.1 Gallbladder (Vesica Biliaris) – 217

8.4.2 Bile Ducts – 217

8.4.3 Blood Supply andDrainage oftheGallbladder andBile Ducts – 217

https://doi.org/10.1007/978-3-662-66735-4_8

8.5 Diseases oftheGallbladder andBile Ducts – 217

https://t.me/medicina_free

8.5.1 Benign Diseases oftheGallbladder – 217

8.5.2 Benign Diseases oftheBile Ducts – 222

8.5.3 Gallbladder Carcinoma – 224

References – 225

Liver, Gallbladder andBile Ducts

https://t.me/medicina_free

201

8.1 Anatomy andPhysiology

oftheLiver

8.1.1 Denitions

5 Liver, gallbladder and bile duct anat-

omy=variable

5 Anatomy of the portal vein branches, the

hepatic veins and the hepatic artery = important in liver surgery

5 Liver function and liver regenera-

tion = central concepts in understanding the techniques of liver surgery

8.1.2 Macroscopic andMicroscopic

Anatomy

Macroscopic Anatomy

Ligaments andLigamentous Attachments

5 Lig. coronarium hepatis (Lig. triangulare

dextrum+Lig. triangulare sinistrum)/coronary ligament (left and right triangle ligament)

5 Lig. falciforme hepatis /falciform ligament

(separates segments 4–8 from segments 2+3)

5 Lig. teres hepatis (obliterated V. umbilica-

lis)/teres hepatic ligament

5 Lig. venosum hepatis (obliterated Ductus

venosus)/veneous hepatic ligament

5 Lig. hepatogastricum and Lig. hepatoduo-

denale (part of the omentum minus)/gastrocolic and hepatoduodenal ligament

Functional Subdivision

5 In segments (according to Couinaud) 5 Oriented to vascular supply 5 Subdivision:

– Right liver lobe (segments 5–8) – Left liver lobe (segments 1–4) – Caudate lobe (segment 1)+Lobus qua-

dratus

– Cava-gallbladder line = dividing line

between right/left liver lobe

Microscopic Anatomy

5 Radial blood ow from portal vein and

arterial blood through hepatic sinusoids to central vein

5 Intercellular transport of bile into bile

ducts

5 Glisson’s triad=interlobular branches of

each portal vein, artery and bile duct

8.1.3 Tasks oftheLiver

andFunctional Liver Volume

Tasks oftheLiver

5 Liver = central metabolic organ with

detoxication and synthesis functions

Blood Formation Site (Embryonic Period)

Protein Biosynthesis andDegradation

5 Under hormonal control 5 In particular, formation coagulation fac-

tors (under the inuence of vitamin K)

5 Protein degradation with formation of

urea (excretion via kidney)

Cleavage ofCarbohydrates andGlycogen Storage

5 Glycogen storage 5 Under the inuence of: adrenaline,

glucagon

Central Organ ofLipometabolism

5 Formation and elimination of lipoproteins

Special Metabolic Services

5 Bilirubin transport 5 Biosynthesis of bile acids

Detoxication Function (Through Biotransformation)

5 Protection of the organism from foreign

substances and drugs

5 In particular by means of cytochrome

P450

202

https://t.me/medicina_free

K. Hoffmann and P. Schemmer

Central Organ oftheTrace Element Metabolism

5 Trace elements: iron, copper, zinc, etc. 5 Numerous vitamins: especially vitamin A

Immunological Function

5 Phagocytosis of cellular elements (out-

dated erythrocytes), bacteria

5 Elimination of immune complexes and

endotoxins

Functional Liver Volume After Resection

Functional Liver Volume After Resection (FLR)

5 Denition: Proportion (in %) of liver vol-

ume that must exist after resection in order to maintain liver function

5 Crucial for predicting liver function after

liver resection

5 Liver disease (Nonalcoholic steatohepati-

tis-NASH) or pre-damage of the liver (chemotherapy associated steatohepatitisCASH) = inuence on functional liver volume after resection

5 Topographical relationship: to the inferior

pleural space+base of the lung

5 Variable with inspiration/expiration

8.1.5 Measured Values

Weight

5 General liver=2.5% of body weight 5 Adult man=approx. 1600g 5 Adult woman=approx. 1400g 5 Volume and weight increased during diges-

tion (blood inow approx. 500g)

Linear Readings

5 Cross diameter (right-left) = 28 cm

(20–40cm)

5 Sagittal diameter (ventral- dorsal) = 8 cm

(5–12cm)

5 Height (cranial-caudal) = 10 cm (up to

27cm)

8.1.6 Blood Supply andDrainage

Blood Supply andDrainage oftheLiver

FLR Targets

5 With normal liver function: FLR ≥20% 5 After chemotherapy: FLR ≥30% 5 In cirrhosis: FLR ≥40%

Measurement ofFLR

5 Mostly by 3D-CT volumetry: direct mea-

surement of total liver volume (TLV)

5 Calculation of the standardized FLR

(sFLR): taking into account the portion to be resected

8.1.4 Location

Position Projection

5 Hepatic superior border: medioclavicu-

lar = fourth intercostal space (ICS); medioaxillary = sixth ICR; paravertebral=eighth ICS

5 Liver inferior border: medioclavicu-

lar=eighth rib; medioaxillary=tenth rib; paravertebral=tenth ICS

Arterial Inow=Hepatic Artery

5 Common hepatic artery: direct outlet from

truncus coeliacus

5 Hepatic artery proper: after delivery A.

gastroduodenalis and A. gastrica dextra

5 Division into right abd kifte hepatic artery 5 Cystic artery: usually from right hepatic

artery

5 Numerous position variations

Numerous variants of arterial inow

5 Aberrant outow from superior mesenteric artery

possible (complete or right hepatic artery)

5 Left hepatic artery partly from left gastric artery or

from coeliac trunc directly

5 Variants with accessory vessels e.g. separate branch

to supply segment 4 from the hepatica propria artery

Portal Venous Inow=portal vein

5 Liver side of the conuence of splenic

vein+superior mesenteric vein, if necessary inferior mesenteric vein (position variants)

Liver, Gallbladder andBile Ducts

https://t.me/medicina_free

203

5 Collaterals: V. coronarian vein + cystic

vein, as well as branches to the pancreatic head

5 Division pattern in liver hilum:

– Right portal venous branch (segments

5–8); subdivision into:

– Anterior pedicle (segments 5 + 8 +

parts of 4 if necessary) +

– Posterior pedicle (segments 6+7)

– Left portal venous branch (segments

2–4)

– Rare trifurcation

Venous Outow

5 Hepatic veins:

– Right hepatic vein (segments 6+7) – Middle hepatic vein (segments 4, 5+8) – Left hepatic vein (segments 2+3) – Norm variant accessory right inferior

hepatic vein (segments 6+7)

5 The hepatic veins open directly subdia-

phragmally into the inferior vena cava

. Fig. 8.1 Functional

subdivision of the liver and terminology of liver resections. (Mod. according to ScottConner 2002)

Right hepatectomy or right hemihepatectomy V–VIII

Extended right hepatectomy

or right trisectionectomy IV–VII

Different variants

5 Common orice of middle+left hepatic vein 5 Direct orice of segmental veins into inferior vena

cava (segment 1)

5 Sonographically distinguishable from portal venous

branches by the absence of a connective tissue sheath

5 Blood supply to the liver: 25% hepatic artery, 75%

portal vein

5 Proportion of oxygenation of liver blood: 40–50%

hepatic artery, 60% portal vein

5 Autoregulation: low portal venous ow leads to

increased arterial ow - hepatic arterial buffer response

8.1.7 Terminology ofLiver

Resections (. Fig.8.1)

5 Consensus Terminology: International

Conference (Belghiti etal. 2000)

Bisegmentectomy II + III

VII

VIII

Left hepatectomy or left hemihepatectomy II–IV

Extended left hepatectomy or left trisectionectomy II–V + VIII

III

204

https://t.me/medicina_free

K. Hoffmann and P. Schemmer

Anatomical (= Typical) Liver Resections

5 Right hemihepatectomy = right hepatec-

tomy: resection of segments V–VIII

5 Left hemihepatectomy=left hepatectomy:

resection of segments II–IV

5 Left-lateral sectorectomy= Bisegmentec-

tomy II+III: Resection of segments II–III

5 Extended right hepatectomy=right trisec-

torectomy: resection of segments IV–VIII

5 Extended left hepatectomy = left trisec-

torectomy: resection of segments II–IV + V + VIII

5 Unclassied adenomas= approx. 10% of

all adenomas

5 Adenomatosis ≥10 adenomas

Epidemiology andRisk Factors

Epidemiology

5 Incidence=3–4/100.000in Europe

Risk Factors

5 Taking oral contraceptives 5 Anabolic Abuse 5 Glycogen storage disorders, galactosemia 5 perfusion disturbances of the liver

Atypical Liver Resections

5 Resections outside the anatomical land-

marks (regardless of the resected liver

volume)

8.2 Diseases oftheLiver

8.2.1 Benign Diseases

Symptoms andComplications

5 Often diagnosed incidentially in asymp-

tomatic patients

5 Possible complications:

– Sponaneous rupture and hemorrhage – Malignant transformation into HCC

(hepatocellular carcinoma), risk 8–13% in β-Catenin-mutated adenomas

Diagnosis

Key Points

5 Adenomas are precancerous and need

to be resected depending on both size and histology

5 Hemangiomas and FNH (focal nodu-

lar hyperplasia) are resected if symptomatic

Hepatocellular Adenomas

Denition andSubtypes

Denition

5 Clonal non-encapsulated neoplasms 5 Mostly from highly differentiated hepato-

cellular cells

Subtypes

5 HNF-1alpha-inactivated adenomas = 40%

of all adenomas; association with MODY type 3

5 Inammatory adenomas=50% of all ade-

nomas, increased risk of bleeding due to ectasia of sinusoidal structures

5 β-Catenin-mutated adenomas, high risk of

malignant transformation (approx. 40%)

5 Sonography 5 MRI 5 Biopsy: indicated for all adenomas

Surgery Indication

5 β-catenin mutated adenomas 5 Adenomas >5cm 5 Adenomas in men—differentiation from

HCC often difcult

5 Adenomas with risk of rupture (in case of

acute bleeding rst embolization, surgery two-sided)

5 Size progression after discontinuation of

oral contraceptives

Focal Nodular Hyperplasia (FNH)

Denition

5 Tumor with hepatocellular origin, poly-

clonal

5 Absence of central and portal veins (=

absence of classical hepatic architecture)

5 Macroscopic: typical picture with central

scar and ochre parenchyma

5 Risk factor: taking estrogen-containing

preparations

Liver, Gallbladder andBile Ducts

https://t.me/medicina_free

205

Epidemiology

5 Second most common benign liver tumor

Diagnosis

5 Sonography 5 MRI 5 Biopsy: not indicated with clear imaging

Complications

5 Progressive growth 5 Rupture 5 Portal hypertension 5 Bleeding: rare 5 Necrosis: rare 5 Malignant degeneration: not described

Therapy

Conservative Approach: Generally

Surgical Therapy

5 Indications:

– Symptomatic patients – Large displacing-growing FNH – Cholestasis – Vascular compression

Hemangiomas

Denition

5 haemangioma of mesenchymal origin

Epidemiology

5 Most frequent benign lesions=0.5–7% of

all patients

5 Women three times more often affected

than men

Clinical Presentation andComplications

Clinical Presentation

5 Mostly incidental ndings and often

asymptomatic

Complications

5 No malignant transformation risk 5 Kasabach-Merritt syndrome:

– Hemangioma bleeding, thrombocyto-

penia and consumption coagulopathy

– Rare complication of generalized giant

hemangiomas

– Mortality risk in case of hemorrhage

30–40%

Diagnosis

5 Sonography (also contrast medium sup-

ported ultrasound)

5 CT 5 Biopsy: not indicated

Therapy

Conservative Therapy

5 Whenever there is no indication for sur-

gery

Surgical Therapy

5 Surgery indication:

– Symptomatic patients – Lesion >5cm – Signicant hemorrhage, location near

the capsule with risk of rupture

– Acute bleeding without the possibility

of control by interventional radiology

Echinococcosis

Denition

5 Tapeworm zoonosis 5 Human=intermediate host 5 Tapeworm species:

– Echinococcus granulosus=Echinococ-

cus cysticus=dog tapeworm

– Echinococcus multilocularis=Echino-

coccus alveolaris=fox tapeworm

Clinical Presentation

E. granulosus (Cysticus, Unilocularis), Dog Tapeworm

5 Displacing growth 5 Infestation of lung and pericardium also

possible

5 Pericyst partly calcied as membrane

around cystic hydatid

5 Often asymptomatic 5 Due to size non-specic upper abdominal

complaints or infection symptoms

206

https://t.me/medicina_free

K. Hoffmann and P. Schemmer

E. multilocularis (alveolaris), Fox Tapeworm

5 Inltrative (tumor-like) growth with for-

mation of small cysts

5 Recognised occupational disease in hunt-

ers and foresters

5 Often asymptomatic 5 Due to size non-specic upper abdominal

complaints or infection symptoms

Diagnosis

5 Incidental nding on imaging 5 Serological: Detection of antibodies 5 Puncture: Contraindicated!

– Installation of compresses soaked in

20% saline solution for 20min=Cau- tion: If bile ducts are opened, bile duct necrosis!—rule out beforehand and over sew bile leaks if necessary

– Suturing of the caspel edge or bipo-

lar coagulation

5 Pericystectomy: Resection of the entire

cyst plus surrounding liver tissue— technically more difcult, risk of rupture!

5 Typical/anatomical liver resection

according to oncological criteria in E. multilocularis

Therapy

Surgical Therapy

5 Whenever possible 5 Only under perioperative medication with

mebendazole or albendazole

5 Treatment only in cooperation with

infectiologists

8.2.2 Malignant Diseases

oftheLiver

Key Points

Surgical Procedure

Surgery for Echinococcosis Cyst

5 Rupture of the cyst and/or extravasa-

tion of cyst uid must be avoided at all costs, otherwise contamination of the situs with the development of disseminated intra-abdominal disease

5 Endocystectomy (procedure of choice

for E. granulosus (Kniepeiss et al.

2020)):

– Repositioning of the liver and the

cyst with cloths soaked in 20% saline solution

– Puncture of the cyst with a dispos-

able trocar+ aspiration of the cyst uid while lling with physiological

saline solution – Uncapping of the cyst – Exclusion of connection to the bile

duct system=e.g. White test (white

fat emulsion approved for i.v. infu-

sion, e.g. lipofundin®, intralipid®

via ductus cysticus)

5 Distinguish primary—such as CCC

(cholangiocarcinoma), HCC (hepatocellular carcinoma)—and secondary malignant ndings (metastases)

Primary Tumors

Hepatocellular Carcinoma (HCC)

Epidemiology andRisk Factors

5 Incidence

– Incidence=10/100.000in Germany

5 Risk factors

– Cirrhosis of the liver of any etiology

(alcohol, hepatitis, hemochromatosis, etc.)

– Chronic hepatitis B/C virus infection

5 Cumulative 5-year risk of developing

HCC in patients with HCV(hepatitis C virus)-associated liver cirrhosis in Europe = about 17%

– Non-alcoholic fatty liver hepatitis

(NASH) as a consequence of diabetes mellitus and the metabolic syndrome— number 1 rising risk factor world wide

– Aatoxin exposure

Liver, Gallbladder andBile Ducts

https://t.me/medicina_free

207

Early Detection

5 Screening program for all patients with:

– Liver cirrhosis – Chronic hepatitis B/C – Fatty liver disease, – Steatohepatitis

5 Sonography every 6months

Special Forms

5 Fibrolamellar HCC—young patients often

better prognosis

5 Mixed differentiated tumors (combined

HCC/intrahepatic cholangiocarcinoma)

5 Early HCC—transition from regenerated

node to HCC

Clinical presentation andClassication

5 Clinical presentation

– Mostly asymptomatic – Conspicuous in routine examinations

of cirrhotic patients

5 TNM classication (HCC)

– T (tumor)

– T1 Solitary tumor without vascular

invasion

– T2 Solitary tumor with vascular inva-

sion or multiple tumors all <5cm – T3a Multiple tumors >5cm – T3b Multiple tumors involving a

major branch of the V. portae or Vv.

hepaticae – T4 Tumor with invasion of adjacent

organs or perforation of the visceral

peritoneum

– N (lymph nodes)

– N0 No locoregional lymph nodes – N1 Locoregional lymph nodes

– M (metastases)

– M0 No distant metastases – M1 Distant metastases – UICC stages according to the TNM

classication (eighth edition, January

2018)

I T1 N0 M0 II T2 N0 M0

IIIA T3 N0 M0 IIIB T4 N0 M0

I VA Any T N1

IVB Each T Each N

Diagnosis

5 Diagnostic imaging

– CM Sonography – Primovist MRI – CT – Characteristic signs in imaging

– Arterial hypervascularization with rapid

washout of the contrast medium and relative contrast reversal to the surrounding liver parenchyma

5 Biopsy

– Only if unclear imaging or therapeutic

consequence

5 Tumor marker

– AFP only suitable for assessment of

progression, not for diagnosis

Surgical Therapy

5 Liver resection (Lin et al. 2012; de San-

tibañes etal. 2017)

– Indications:

– Patients with potentially resectable

HCC without cirrhosis

– Patients with potentially resectable

HCC and Child A/B cirrhosis

– Presence of portal hypertension (asci-

tes, platelets <100.000, splenomegaly)=not a sole exclusion criterion for resection, but signicantly increases the surgical risk

– Atypical resections=leaving as much

functional liver tissue as possible

– 5-year survival = 30–50%, but high

recurrence rates due to de novo tumors in cirrhosis or micrometastases

5 Liver transplantation (Lin etal. 2012)

– Indications depending on local/national

legal regulations and/or guidelines

– Treatment of HCC + underlying liver

cirrhosis

– Prioritization and organ distribution

according to local/national legal regulations and/or guidelines (Eurotransplant region—MELD (Model for End-Stage Liver Disease) score based:

– Patients receive extra points with

increasing waiting time)

– Transarterial chemoembolisation

(TACE), local thermal ablation (up to 3cm diameter), liver resection: allows

<<< < Предыдущая 11 12 13 14 15 16 17 18 19 20 21 2223 / 4023 24 25 26 27 28 29 30 31 32 33 34 35 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
31.08.202622 Мб0Инфекции в хирургии.pdf
#
30.08.202656 Мб0Книга_100_библиотеки_им_акад_М_И_Перельмана.pdf
#
31.08.202626 Мб0Книга_1000_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202626 Мб0Книга_1001_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202626 Мб0Книга_1002_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202626 Мб0Книга_1004_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202625 Мб0Книга_1005_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202625 Мб0Книга_1006_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202625 Мб0Книга_1007_Библиотеки_им_академика_М_И_Перельмана.pdf
#
31.08.202625 Мб0Книга_1008_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202652 Мб0Книга_101_библиотеки_им_акад_М_И_Перельмана.pdf